| Company/Website |
Description |
Acuity Pharmaceuticals
www.acuitypharma.com |
Leverages its strong technology and intellectual property portfolio in the exciting new field of RNA interference (RNAi) for the treatment and prevention of opthalmic diseases. |
Aprecia Pharmaceuticals Company
www.aprecia.com |
Aprecia Pharmaceticals Company has developed a unique methodology to manufacture rapidly dispersing oral pharmaceuticals at a dosage level not yet achieved by competing technologies. Aprecia uses Three Dimensional Printing (3DP) technology developed at M.I.T. to produce oral wafers, which can disperse in less than five seconds while delivering a dosage loading of greater than 50 mg.
|
Bionanomatrix, LLC
www.bionanomatrix.com |
BioNanomatrix (BNM) is a bionanotech designer and maker of nanostructured chips, devices and systems for fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single cell / single molecule level. Currently, BNM develops nanodevices and systems for cancer diagnostics, complex disease therapeutics and personalized medicine on its NANOANALYZER™ platform. |
BioSyn, Inc.
(Acquired by
Cellegy Pharmaceuticals
Nasdaq: CLGY)
www.biosyn-inc.com |
An anti-infective drug company developing novel, targeted-delivery drugs for the treatment and prevention of infectious diseases in the area of AIDS/HIV. |
DermAvance Pharmaceuticals
www.dermavance.com |
DermAvance markets and sells anti-aging facial products. The company markets both prescription and cosmeceutical products to dermatologists and plastic surgeons in order to capitalize on the growth aesthetic side of the dermatology business and the rapidly growing demand for rejuvenation products. |
Devine Foods, Inc.
www.devinefoods.com |
Develops and markets innovative, patented whole food products, ingredient bases and neutraceuticals that facilitate healthy lifelong eating patterns. |
Dynamis Therapeutics, Inc.
www.dynamis-therapeutics.com |
A drug discovery company focusing on the development of new pharmaceuticals and diagnostics for the treatment of diabetic complications, aging and Alzheimer's disease. |
Eagle Vision
|
Develops a cardiovascular imaging agent by use of Magnetic Resonance Imaging. |
Exocell
www.exocell.com |
A leading developer of drugs to prevent and treat complications of diabetes, such as kidney and eye disease. |
Immune Control
www.immunecontrol.com |
Conducts research and development on seratonin receptor antagonists for treatment of cancers and immunologic disorders. |
Immunotope, Inc.
www.immunotope.com |
A Phase I clinical stage company developing safe and effective immunotherapy
products for the treatment and prevention of cancer and chronic viral infections. |
Jenrin Discovery, LLC
www.jenrindiscovery.com |
Jenrin Discovery develops drugs for the treatment of inflammatory and metabolic disorders, including obesity. |
MacroArray Technologies, LLC.
www.macroarraytech.com |
Develops novel products by linking diagnostic and therapeutic medicine to rapidly identify marker genes that are critical to cancer cell growth and survival. The company's lead product is a urine based prostate diagnostic. |
Midway Pharmaceuticals, Inc.
|
A biotechnology company, engages in the development of nonantibiotic therapies for gastrointestinal diseases. It develops therapies for the treatment of Crohn's disease, ulcerative colitis, necrotizing enterocolitis, and inflammatory bowel diseases. |
NanoVec, Inc.
www.nanovec.com |
NanoVec, Inc. is an early stage biotechnology company developing novel nanobiomolecular platforms for vaccines and therapeutics against infectious diseases, biothreats and cancer |
NexusPharma, Inc.
www.nexuspharma.com |
NexusPharma is a unique biopharmaceutical company dedicated to the discovery of novel therapeutics by modulating protein-protein interactions with small molecules. Applying its patented technologies discovered at Fox Chase Cancer Center, NexusPharma is developing novel, non-cytotoxic anti-cancer agents based on small-molecule protein-protein interaction inhibitors. |
Niiki Pharma, Inc.
www.niikipharma.com |
Niiki Pharma Inc. is a cancer drug development company founded by experienced biotech and pharmaceutical company executives. The company is developing three novel drug candidates with mechanisms of action that differ from cancer treatments currently on the market and which are designed to preferentially target the cancer cells. Two of these compounds have been tested in patients. |
NuPathe, Inc.
www.nupathe.com |
NuPathe, Inc. is a development stage pharmaceutical company founded in early 2005 that is specializing in the acquisition and development of neuroscience therapeutics. The mission of NuPathe is to identify opportunities for therapeutic advances in the treatment of neurologic and psychiatric disorders and to license and develop compounds and technologies that meet these needs. |
Onconova Therapeutics, Inc
www.onconova.com |
Onconova is building a diversified program in cancer therapy and proliferative disorders based on their competencies in medicinal chemistry, cell cycle molecular biology, drug development and cancer related genomics. |
Othera Pharmaceuticals
www.othera.com |
Designs and develops proprietary ophthalmic drugs targeting cataracts, glaucoma, and dry AMD. |
PhenoTech, Inc.
www.phenotech.com |
PhenoTech develops novel blood typing reagents. PhenoTech's technology is expected to represent the first significant advance in a 50-year-old agglutination-based process. This technology should result in a reduction in potential negative transfusion reactions with a concomitant reduction in sensitization to foreign blood cell antigens. |
Protez Pharmaceuticals
www.protez.com |
Discovery and developing novel antibiotics for use in hospitals. |
PTI Research, Inc.
|
A biopharmaceutical company with a compound targeting the prevention restinosis, a disease characterized by the re-closing of areteries after balloon angioplasty. |
RetinaPharma Technologies
www.retinapharma.com |
Develops products for the prevention, treatment and diagnosis of vision disorder and eye diseases such as macular degeneration and retinitis pigmentosa. |
TheraQuest Biosciences
www.theraquestinc.com |
TheraQuest Biosciences is a development stage pain management company with a diversified portfolio of products for the treatment of acute and chronic pain. |
Topaz Pharmaceuticals, LLC
www.topazpharma.com |
Topaz Pharmaceuticals LLC is a start-up company that plans to develop and market pediatric medicines. The company has identified a significant unmet need for pediatrically oriented pharmaceuticals and vaccines beginning with a product to treat the pervasive issue of head lice in children aged 0 - 13. |
Yaupon Therapeutics, Inc.
www.yaupontherapeutics.com |
Yaupon Therapeutics is developing potentially ground-breaking treatments for conditions such as drug addiction and cancer from compounds found in plants. The most advanced product in Yaupon's pipeline, Lobeline, is being developed to help drug users hooked on methamphetamines to overcome addition. |
